BioSpace News Archive

Frequency Therapeutics, Inc. today announced that it has completed enrollment of its placebo-controlled Phase 2b study of FX-322 in adults with acquired sensorineural hearing loss (SNHL).

MaxCyte, Inc. today announced that it will release financial results for the third quarter of 2022 after the U.S. market close on Wednesday, November 9th , 2022.

Lewy Body Dementia patients are actively being recruited by Cognition Therapeutics, Inc. and its clinical partners for the SHIMMER Phase 2 trial of their CT1812 oral drug therapy at 17 study sites across the country with more expected to open.

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that its abstract on camsirubicin submitted to the 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting has been selected for a poster presentation.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today announced the inaugural International Meeting on Pathway-Related Obesity: Vision of Excellence (IMPROVE) 2022 in Berlin, Germany from October 12-14.

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer, and Dr. Michelle Berrey, President of R&D and Chief Medical Officer of Intercept will participate in a fireside chat at H.C. Wainwright’s 6th Annual NASH Investor Conference.

Femasys Inc., a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, announced the appointment of Christine Thomas, RAC, as senior vice president of regulatory and clinical affairs, effective October 10, 2022.

Bioventus Inc., a global leader in innovations for active healing, will present its spine procedural solutions portfolio at the North American Spine Society meeting in Chicago, October 12 through 15.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase) today announced that Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase, will present at the Cambridge Healthtech Institute’s Inaugural Neurodegeneration Targets: Drug Discovery for Brain and Nerve-Related Progressive Disorders Conference.

Salix Pharmaceuticals, the gastroenterology business of Bausch Health Companies Inc., released the Salix Liver Health Annual Trends Report, Second Edition with the latest information on chronic liver disease care and findings that include a continued rise in hospitalizations and mortality from CLD and cirrhosis, as well as gaps in care and knowledge that may prevent early diagnosis and optimal management of CLD, cirrhosis and its complications.